These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 30144048

  • 21. Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A.
    Naganawa M, Gallezot JD, Finnema SJ, Maguire RP, Mercier J, Nabulsi NB, Kervyn S, Henry S, Nicolas JM, Huang Y, Chen MK, Hannestad J, Klitgaard H, Stockis A, Carson RE.
    EJNMMI Res; 2022 Nov 08; 12(1):71. PubMed ID: 36346513
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H.
    Br J Pharmacol; 2008 Aug 08; 154(8):1662-71. PubMed ID: 18500360
    [Abstract] [Full Text] [Related]

  • 24. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
    Hirsch M, Hintz M, Specht A, Schulze-Bonhage A.
    Seizure; 2018 Oct 08; 61():98-103. PubMed ID: 30118932
    [Abstract] [Full Text] [Related]

  • 25. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E, Gambardella A, De Sarro G, Russo E.
    Drug Des Devel Ther; 2015 Oct 08; 9():5719-25. PubMed ID: 26543353
    [Abstract] [Full Text] [Related]

  • 26. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
    Rassu M, Biosa A, Galioto M, Fais M, Sini P, Greggio E, Piccoli G, Crosio C, Iaccarino C.
    J Cell Mol Med; 2019 Dec 08; 23(12):8505-8510. PubMed ID: 31560168
    [Abstract] [Full Text] [Related]

  • 27. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC, Geldard J, Peacey C, Wright E, Eltayeb K, Maguire M.
    Epilepsy Behav; 2019 Oct 08; 99():106505. PubMed ID: 31493736
    [Abstract] [Full Text] [Related]

  • 28. Brivaracetam: a novel antiepileptic drug for focal-onset seizures.
    Stephen LJ, Brodie MJ.
    Ther Adv Neurol Disord; 2018 Oct 08; 11():1756285617742081. PubMed ID: 29399049
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, Schiemann J, Whitesides J.
    Epilepsy Res; 2017 Mar 08; 131():70-75. PubMed ID: 28279891
    [Abstract] [Full Text] [Related]

  • 30. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M, Mandarano M, Romozzi M, Eusebi P, Bedetti C, Nardi Cesarini E, Verzina A, Calvello C, Loreti E, Sidoni A, Giovenali P, Calabresi P, Costa C.
    J Neurol; 2019 Sep 08; 266(9):2273-2276. PubMed ID: 31168673
    [Abstract] [Full Text] [Related]

  • 31. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M, Chatelain P, Fuks B.
    Eur J Pharmacol; 2006 Apr 24; 536(1-2):102-8. PubMed ID: 16556440
    [Abstract] [Full Text] [Related]

  • 32. Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein.
    Okada M, Fukuyama K, Shiroyama T, Ueda Y.
    Biomed Pharmacother; 2021 Jun 24; 138():111462. PubMed ID: 33706129
    [Abstract] [Full Text] [Related]

  • 33. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.
    Wu PP, Cao BR, Tian FY, Gao ZB.
    Neurosci Bull; 2024 May 24; 40(5):594-608. PubMed ID: 37897555
    [Abstract] [Full Text] [Related]

  • 34. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J, Anderson D, Lynch BA, Castaigne JG, Foerch P, Lebon F.
    Biochem Soc Trans; 2011 Oct 24; 39(5):1341-7. PubMed ID: 21936812
    [Abstract] [Full Text] [Related]

  • 35. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I, von Podewils F, Möddel G, Bauer S, Klein KM, Paule E, Reif PS, Willems LM, Zöllner JP, Kunz R, Runge U, Kurlemann G, Schubert-Bast S, Rosenow F, Strzelczyk A.
    Epilepsia; 2017 Jul 24; 58(7):1208-1216. PubMed ID: 28480518
    [Abstract] [Full Text] [Related]

  • 36. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities.
    Theochari E, Cock H, Lozsadi D, Galtrey C, Arevalo J, Mula M.
    Epilepsy Behav; 2019 Jan 24; 90():129-131. PubMed ID: 30530134
    [Abstract] [Full Text] [Related]

  • 37. Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam.
    Schoemaker R, Krauwinkel W, Elshoff JP, Stockis A.
    Epilepsy Res; 2024 May 24; 202():107332. PubMed ID: 38518434
    [Abstract] [Full Text] [Related]

  • 38. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM, Tate SK, Kinirons P, Weale ME, Cavalleri GL, Depondt C, Murphy K, O'Rourke D, Doherty CP, Shianna KV, Wood NW, Sander JW, Delanty N, Goldstein DB, Sisodiya SM.
    Epilepsy Res; 2009 Jan 24; 83(1):44-51. PubMed ID: 18977120
    [Abstract] [Full Text] [Related]

  • 39. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.
    Menzler K, Mross PM, Rosenow F, Schubert-Bast S, Willems LM, Zahnert F, Immisch I, Fuest S, von Podewils F, Kunz R, Hirsch M, Mueller T, Marquetand J, Winter Y, Langenbruch L, Cicanic M, Beyenburg S, Strzelczyk A, Knake S.
    BMJ Open; 2019 Nov 04; 9(11):e030746. PubMed ID: 31690606
    [Abstract] [Full Text] [Related]

  • 40. Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis.
    Lee J, Daniels V, Sands ZA, Lebon F, Shi J, Biggin PC.
    PLoS One; 2015 Nov 04; 10(2):e0116589. PubMed ID: 25692762
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.